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This assessment revealed that placebo-subtracted mortality changes among the trials were directly proportional to placebo-subtracted heart rate changes.
This relationship was most strongly influenced by the trials of beta-blocking drugs by then available, but extended to non-beta-blockers as well. Subsequent meta-regression analyses confirmed these findings (2,3) and further indicated that the mortality benefit was highly significantly related to heart rate reduction, but not at all to beta-blocker dose (2).
However, the beta-blocker trials were based on hypotheses about the net effect of all beta-blocker pharmacological actions, in addition to heart rate slowing, which might, in theory, improve myocardial function; no target heart rates were developed for use of the drugs. The relatively recent availability of ivabradine, a "pure" heart rate-slowing drug, has allowed evaluation specifically of the benefit of heart rate reduction, separate from other pharmacological effects. Ivabradine seems to have only 1 action on the cardiovascular system, that of blocking f-channels in sinoatrial nodal cells, thereby reducing or eliminating the small f-current (I f ) generated across these channels. Physiologically, this current increases heart rate by increasing the slope of spontaneous sinoatrial diastolic depolarization (itself a function of ion movement through calcium and potassium channels). Administration of ivabradine enables rigorous testing of the hypothesis that heart rate lowering, alone, provides important benefit to patients with systolic HF. This hypothesis is highly plausible: the "mechanism" of such benefit is not fully understood, but it is known that in the failing myocardium, high-energy substrates are relatively deficient; increasing heart rate increases demand for this resource while decreasing the myocardial perfusion that could help to replenish it. 
among patients with moderate-to-severe symptoms, left ventricular ejection fraction #35% and heart rate at rest $70 beats/min (5). The trial was highly positive, demonstrating an 18% reduction of the primary composite endpoint compared with placebo, 26% reduction in HF hospitalizations, and 26% reduction in death attributable specifically to HF. Importantly, by virtue of the study design, benefit only could be inferred in patients whose heart rate, for whatever reason (drug intolerance, adverse drug effects, insensitivity to drugs, and so on) could not be lowered to <70 beats/min with beta-blockers alone.
Moreover, though beta-blockade is a mainstay of therapy for systolic HF, multiple registries indicate that more than one-half the affected patients maintain heart rates in excess of 70 beats/min (often far in excess) despite beta-blockade (6,7) and other therapies. Therefore, it is expected that many patients can benefit from addition of ivabradine. However, this assumption never had been rigorously evaluated. In this issue of JACC: Heart Failure, rates >75 beats/min, for whom there is high likelihood of reduction in mortality alone). Conversely, ivabradine is devoid of several of the adversities associated with beta-blockers (exacerbation of pulmonary disease [9] , conduction abnormalities [10] , diabetes [11] , and so on), thus suggesting that the drug will be prescribed in many patients whose heart rate could be lowered with higher beta-blocker doses alone but who cannot tolerate such dose increases.
The Dierckx et al. (8) (14) .
Using the authors' proportions, this suggests that at least 600,000 persons in the United States and elsewhere can benefit from addition of ivabradine to lower heart rate to improve survival and/or reduce hospitalization frequency (and in addition, to enhance quality of life [15] , not affected by beta-blockers); these numbers increase annually. gmail.com.
